Cancer immunotherapy strategies that target the cGAS-STING pathway

Activation of the cGAS-STING pathway by cytoplasmic DNA induces the production of Type-1 interferons. Recent advances in research suggest that the cGAS-STING pathway is involved in different parts of the cancer-immunity cycle (CIC) to promote or suppress antitumor immune responses. Combination therapy of STING agonists has made certain progress in preclinical as well as clinical trials, but the selection of combination therapy regimens remains a challenge. In this review, we summarize the role of the cGAS-STING in all aspects of CIC, and focus on the combination immunotherapy strategies of STING agonists and current unsolved challenges.

Automated summary

Activation of the cGAS-STING pathway by cytoplasmic DNA leads to the production of Type-1 interferons, which play a critical role in cancer-immunity cycle. Research has shown that combination therapy of STING agonists has made progress in preclinical and clinical trials, but selecting appropriate combination therapy regimens remains a challenge.